Prescription medicine
Methylergonovine Brand names: Methergine
Methylergonovine (Methergine) is a prescription medicine with an FDA approval on record since 1946. FDA's NDC Directory lists it from 14 generic labelers, and pharmacies paid $4.50 per methylergonovine 0.2 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the methylergonovine FDA label on DailyMed (effective May 1, 2026, Teva Pharmaceuticals USA, Inc.); the NDA 6035 record on Drugs@FDA; every methylergonovine label on DailyMed.
Highlights of the record
FDA label of May 1, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFollowing delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus.
Forms and strengths
- 0.2 mg
- 0.2 mg/ml
Tablet; injection; injection (solution).
On the market
- Earliest approval on file
- November 19, 1946 Methergine, Edison Theraps Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 8 first November 24, 2008; 8 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 14 of which 14 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.50 per tablet Methylergonovine 0.2 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 4 since 2013 0 Class I among all firms' recalls; latest June 16, 2026
- FAERS reports
- 665 through July 30, 2026
What is methylergonovine used for?
From the label: indications and usageFollowing delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.
FDA pharmacologic class: Ergot Derivative.
Source: FDA drug label (Methylergonovine Maleate), Teva Pharmaceuticals USA, Inc., effective May 1, 2026 (SPL set d8e4b8ed-3289-4611-8a61-2392a4bf6072), via openFDA; the full label on DailyMed
Is there a generic for methylergonovine (Methergine)?
The FDA approved the first generic methylergonovine on November 24, 2008. 8 generic applications are approved; 8 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists methylergonovine from 14 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1946 earliest approval on file
- 2008 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for methylergonovine (Methergine)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.50 per Methylergonovine 0.2 mg tablet, down 19% from $5.53 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Methylergonovine 0.2 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Methylergonovine 0.2 mg tablet | Generic | $4.50 per tablet | $134.92 | -19% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has methylergonovine been recalled?
The FDA's Enforcement Report lists 4 recalls naming methylergonovine since 2013: 0 Class I (the most serious), 3 Class II, 1 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 16, 2026 | Class II | The Harvard Drug Group LLC | Subpotent Drug |
| March 25, 2024 | Class II | Amneal Pharmaceuticals of New York, LLC | Failed Dissolution Specifications |
| July 18, 2019 | Class III | Amneal Pharmaceuticals, Inc. | Presence of Foreign Tablet/Capsule; one Promethazine tablet was found in a bottle of Methylergonovine Maleate tablets |
| July 2, 2013 | Class II | Aidapak Services, LLC | Labeling: Label Mixup; METHYLERGONOVINE MALEATE Tablet, 0.2 mg may be potentially mislabeled as ISOSORBIDE MONONITRATE, Tablet, 20 mg, NDC 62175010701 … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the methylergonovine label say about other medicines?
The methylergonovine label names 17 other medicines in its interaction, contraindication or warning sections. The labels of 20 other medicines name methylergonovine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Chlorzoxazone | drug interactions | Weak CYP 3A4 inhibitors should be administered with caution. Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. |
| Cilostazol | drug interactions | Weak CYP 3A4 inhibitors should be administered with caution. Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. |
| Clarithromycin | drug interactions | … inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). … |
| Clotrimazole | drug interactions | … (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
| Dihydroergotamine | drug interactions | Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm … |
| Ergotamine | drug interactions | Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm … |
| Fluconazole | drug interactions | … nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
| Fluvoxamine | drug interactions | … azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
| Itraconazole | drug interactions | … transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
| Ketoconazole | drug interactions | … protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
| Nefazodone | drug interactions | Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g. … |
| Nelfinavir | drug interactions | … troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
| Nevirapine | drug interactions | CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. |
| Ranitidine | drug interactions | Weak CYP 3A4 inhibitors should be administered with caution. Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. |
Every other medicine the methylergonovine label names
| Medicine named | Section | What the label says |
|---|---|---|
| Rifampin | drug interactions | CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. |
| Ritonavir | drug interactions | … clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). … |
| Voriconazole | drug interactions | … nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. |
Other labels that name methylergonovine
Source: FDA drug label (Methylergonovine Maleate), Teva Pharmaceuticals USA, Inc., effective May 1, 2026 (SPL set d8e4b8ed-3289-4611-8a61-2392a4bf6072), via openFDA; the full label on DailyMed
What do FAERS reports show for methylergonovine?
The FDA Adverse Event Reporting System holds 665 reports that list methylergonovine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 41 are coded as a death and 271 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other ergot derivatives
- the pharmacologic class, with prices and generics
- Methylergonovine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other